Dataset from Effect of LY2062430, an Anti-Amyloid Beta Monoclonal Antibody, on the Progression of Alzheimer's Disease as Compared With Placebo

Alzheimer's disease (AD) is an age-related degenerative disorder of the brain, characterized
by progressive decline in cognitive function and ability to perform activities of daily
living, and ultimately can lead to death due to complications of the disease. AD is thought
to be caused by an excess of A-Beta amyloid, a sticky protein in the brain that forms amyloid
plaques. Treatments that slow the synthesis or deposition of A-Beta amyloid, or that increase
clearance, might be expected to slow the progression of AD.

LY2062430 (solanezumab) is a humanized anti-A Beta peptide immunoglobulin G-1 (IgG1)
monoclonal antibody being developed for the treatment of AD. The primary hypothesis being
tested is that LY2062430 will slow cognitive and functional decline in AD as compared with
placebo. Each patient's participation will last approximately 19 months. Patients taking
approved AD medications may participate in this study and continue taking these medications
during the study.

阿尔茨海默病（AD）是一种年龄相关性脑退行性疾病，以认知功能与日常生活活动能力进行性减退为特征，最终可因该病并发症导致死亡。目前认为，阿尔茨海默病的发病与脑内β淀粉样蛋白（A-Beta amyloid）过量相关——该蛋白为一种粘性蛋白，可在脑内形成淀粉样斑块。能够减缓β淀粉样蛋白合成与沉积、或促进其清除的治疗手段，有望延缓阿尔茨海默病的病情进展。

LY2062430（索拉珠单抗，solanezumab）是一种正被开发用于阿尔茨海默病治疗的人源化抗Aβ肽免疫球蛋白G1（IgG1）单克隆抗体。本研究拟验证的核心假说为：与安慰剂组相比，LY2062430可延缓阿尔茨海默病患者的认知与功能减退。每位受试者的研究周期约为19个月。已获批的阿尔茨海默病治疗药物使用者可参与本研究，并可在研究期间继续服用此类药物。